Colorectal Cancer Risk Assessment Using Genotype-Specific Antigen Thresholds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical analysis systems for colorectal cancer screening have low sensitivity and high false positive rates due to their reliance on tumor markers alone, without considering genetic variations that affect antigen levels.
Innovation Solution
A medical analysis system that receives CA 19-9 and CEA antigen levels and FUT2 and FUT3 genotypes, assigns these to predefined genotype groups, and uses specific antigen threshold levels associated with each group to determine colorectal cancer risk, thereby enhancing screening sensitivity and reducing false positives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tumor marker levels alone are used for colorectal cancer screening, then the screening procedure is simple and easily available, but the sensitivity is low and false positive rates are high
Solution Approach 1:
The patent combines tumor marker analysis (CA 19-9, CEA) with genetic genotype analysis (FUT2, FUT3) into a single integrated screening system. This merging of two different analytical approaches allows the system to achieve high sensitivity by considering both phenotypic marker levels and genotypic predisposition, while resolving the contradiction between simplicity and accuracy.
Solution Approach 2:
The patent changes the evaluation parameters from fixed tumor marker thresholds to dynamic, genotype-specific thresholds. By determining antigen threshold levels based on the patient's FUT2 and FUT3 genotype combinations, the system adapts the screening criteria to individual genetic characteristics, thereby improving sensitivity and reducing false positives without requiring overly complex manual interpretation.
2Measurement precision
If genotype-specific antigen threshold levels are used, then screening sensitivity is enhanced and false positives are reduced, but the complexity of the analysis system increases
Solution Approach 1:
The system performs preliminary genotyping analysis (FUT2 and FUT3) before establishing the antigen threshold levels for tumor markers. By determining the genetic background first, the system pre-calculates the appropriate threshold values, which simplifies the subsequent interpretation of tumor marker levels and improves diagnostic accuracy without requiring complex real-time calculations during the screening process.
Solution Approach 2:
The patent implements dynamic parameter adjustment where antigen threshold levels are changed based on genotype results. The system automatically selects appropriate threshold values from predefined ranges corresponding to different genotype groups, thereby achieving precise, individualized diagnostic criteria while maintaining system simplicity through automated parameter selection rather than manual adjustment.
3Ease of operation
If simple tumor marker screening is used, then the screening is easily available at many medical practices, but the number of false positive results is high
Solution Approach 1:
The patent segments the patient population into distinct genotype groups based on FUT2 and FUT3 combinations. By dividing the homogeneous screening approach into heterogeneous genotype-specific categories, the system can apply appropriate threshold levels to each segment, thereby reducing false positives within each group while maintaining the overall simplicity and accessibility of the screening program across diverse populations.
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
The invention relates to a medical analysis system (100) comprising - a first interface (112) being operable for receiving an antigen level, wherein the antigen level is a CA 19-9 antigen level and/or a CEA antigen level, - a second interface (110) being operable for receiving an FUT2 genotype and an FUT3 genotype, - an first assigning module (114) being operable for assigning the FUT2 genotype and the FUT3 genotype combination to a genotype group type of a set of predefined genotype group types, said assigning resulting in an assigned genotype group type, - a selection module (116) comprising an association of an antigen threshold level to each genotype group type of the set of predefined genotype group types, wherein the antigen threshold level is a CA 19- 9 antigen threshold level and/or a CEA antigen threshold level, wherein the selection module (116) is operable for selecting from the association the antigen threshold level associated with the assigned genotype group type and for determining if the antigen level is above the selected antigen threshold level, - a third interface (118) being operable for providing an indication on a risk for colorectal cancer in case the antigen level is above the selected antigen threshold level.